Creating breakthrough therapeutics with glycomics
Synedgen is a pioneering biotechnology company using the science of glycomics to discover and develop drugs that enhance and mimic the innate immune system.
New class of glycopolymer-based therapeutics
Our innovative glycomics platform targets complex cell surface and mucosal interface interactions in diverse clinical ecosystems. The mucosal surface provides the body’s natural barrier to infection and damage from outside contaminants and pathogens.
Our pipeline continues to leverage these successes to develop gastrointestinal and ophthalmic drugs. We have also applied our expertise to develop medical device products to improve oral, wound, and sinus health.
Select Synedgen products have been developed in part with support from the National Institutes of Health, DARPA, the National Institute of Allergy and Infectious Disease, and the US Army Medical Research and Materiel Command.
Creative solutions to difficult chemistry problems and unmet medical needs
Synedgen takes a unique scientific and applied clinical approach. Our technology simplifies the process to discover, develop and manufacture modified polysaccharides designed for therapeutic impact. We apply our platform strategically to address medical needs that cannot be met by other technologies, and translate these innovations into effective treatments.
Through our highly specialized, robust and predictive technology engine, we solve difficult chemistry problems previously inaccessible to traditional approaches. We have identified chemical properties required to ultra-purify glycopolymers and designed chemical modifications to make the drugs soluble, active and targeted in the human body.
Our chemistry advantage produces a scientifically validated pipeline of drugs able to:
- Mimic the body’s innate immune response to reduce inflammation and improve healing.
- Protect mucosal surfaces from damage and microbial imbalance.
- Control mucosal inflammation after damage and restore homeostasis.
- Reduce the ability of bacteria to bind and invade tissues.
- Restore the native environment to support the normal microbiome.
The image below represents the role that differences in ion interactions at the cellular level play in driving diseases affecting the mucosal interface and suggests potential therapeutic approaches. This model has important implications for the design of mucosal drug delivery and therapeutics. James D. Sterling and Shenda M. Baker reported this research in Macromolecular Theory and Simulations. Image courtesy of KC Jones.
Synedgen has a broad US and international patent estate. The IP portfolio covers the overall platform as well as use and compositions of matter for the specific products under development.